Clinical Trials Logo
  1. Home
  2. Cutaneous T-Cell Lymphoma
  3. NCT03932279
  4. Details
NCT03932279 Clinical Trial

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Cutaneous T Cell Lymphoma Clinical Trial

Official title:
Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03932279
Other study ID # XZ05212018
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 30, 2019
Est. completion date August 31, 2028

Study information
Verified date March 2024
Source Northwestern University
Contact Dermatology CTU
Phone 312-503-5944
Email NUderm-research@northwestern.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date August 31, 2028
Est. primary completion date February 28, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Group 1: Patients with stage IA-IIA cutaneous T cell lymphoma - Group 2: Patients with stage IIB and above cutaneous T cell lymphoma - Group 3: Patients with CD30+ lymphoproliferative disorder including lymphomatoid papulosis and cutaneous anaplastic large cell lymphoma - Group 4: Patients with plaque psoriasis with BSA>5% on routine phototherapy per standard of care - Group 5: Patients with moderate to severe atopic dermatitis on routine bleach bath therapy per standard of care - Group 6: Healthy individuals without the above skin conditions, similar age and sex distribution to the patients with cutaneous T cell lymphoma - All Groups: subjects who are age 18-89 years of age at time of enrollment - All Groups: Subjects who are able and willing to give informed consent for this study and the Dermatology Tissue Acquisition and Biorepository (STU00009443). Exclusion Criteria: - All Groups: Subjects who are younger than 18 years of age or older than 90 years of age - All Groups: Subjects who are unable to give consent - Patients currently on systemic antibiotics or recent (within past 4 weeks) exposure to systemic antibiotics - We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (1)
Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Bacterial diversity index Diversity analysis of microbiome samples (measured by number of bacteria species/sample) 3 months
See also
  Status Clinical Trial Phase
Completed NCT02546440 - Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) Phase 2
Recruiting NCT04014374 - Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Active, not recruiting NCT01460914 - Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Completed NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Phase 1
Recruiting NCT02539472 - Early Diagnosis of Mycosis Fungoides N/A
Recruiting NCT06436677 - A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Recruiting NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides Phase 2
Recruiting NCT01132989 - Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Phase 2
Recruiting NCT05414500 - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Phase 1
Terminated NCT01663571 - STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
Active, not recruiting NCT02192021 - Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Phase 1
Recruiting NCT05781386 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors Phase 1
Active, not recruiting NCT02576496 - Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT03775525 - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Phase 1
Withdrawn NCT03235869 - Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma Early Phase 1
Active, not recruiting NCT01396070 - Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level N/A
Completed NCT01198665 - RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Phase 1/Phase 2
Not yet recruiting NCT05728879 - Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution Early Phase 1
Not yet recruiting NCT06113081 - Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma